BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis in newborns1 as well as healthcare-associated infections, including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis2. Klebsiella pneumoniae has developed resistance to many classes of antimicrobials and was attributed to or associated with an estimated 600,000 deaths globally in 20193.
Read More: BusinessWire - Jornalwebdigital
0 Comentários